Sylvia Tobé is a biotech industry professional with more than 10 years of experience across venture investing, company creation, and translational science. Prior to joining the T1D Fund, she was a Principal at Omega Funds, where she focused on early-stage investments and company formation across various therapeutic areas including neurology, immunology, and rare diseases. She currently serves on the Boards of DiogenX, ZagBio and Islex Therapeutics and has held Board observer roles at various biotech companies including Zucara Therapeutics, Vanqua Bio, Rectify Pharma and others.

Before Omega, Sylvia spent nearly seven years at Ra Pharmaceuticals, a peptide drug discovery company focused on complement-driven rare diseases. At Ra, she contributed to the development of the company’s discovery platform and helped build preclinical and translational models supporting first-in-human studies for its lead program, Zilucoplan, now approved in multiple countries for generalized myasthenia gravis (gMG). She also provided scientific leadership across multiple internal and partnered discovery programs, including a collaboration with Merk.

Sylvia earned her Ph.D. in Biochemistry (Summa Cum Laude) from Pierre and Marie Curie University in Paris while serving as a full-time visiting fellow in the Department of Genetics at Harvard University, where she worked in synthetic biology. She also holds an M.S. from Pierre and Marie Curie University and a B.S. in Biochemistry from Joseph Fourier University in Grenoble.

Lucio Iannone is a healthcare investor with more than 15 years of experience spanning venture capital, board leadership, and biotechnology. Prior to joining the T1D Fund, he served as Head of Health Investments at Leaps by Bayer, where he led the global investment team, shaped investment strategy, and directed deal execution across a portfolio with more than $1 billion in assets under management.

Lucio has served on the boards of over 18 companies. His scientific and investment background includes deep expertise in molecular biology, cell and gene therapy, and therapeutic innovation across oncology, autoimmune disease, and cardiovascular health.

Lucio earned his Ph.D. in Medicine from Imperial College London and is passionate about advancing novel therapeutics and supporting the next generation of transformative healthcare companies.